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Abstract
Rationale—The Early Pseudomonal Infection Control (EPIC) randomized trial rigorously
evaluated the efficacy of different antibiotic regimens for eradication of newly identified
Pseudomonas (Pa) in children with cystic fibrosis (CF). Protocol based therapy in the trial was
provided based on culture positivity independent of symptoms. It is unclear whether outcomes
observed in the clinical trial were different than those that would have been observed with
historical standard of care driven more heavily by respiratory symptoms than culture positivity
alone. We hypothesized that the incidence of Pa recurrence and hospitalizations would be
significantly reduced among trial participants as compared to historical controls whose standard of
care preceded the widespread adoption of tobramycin inhalation solution (TIS) as initial
eradication therapy at the time of new isolation of Pa.
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Methods—Eligibility criteria from the trial were used to derive historical controls from the
Epidemiologic Study of CF (ESCF) who received standard of care treatment from 1995 to 1998,
before widespread availability of TIS. Pa recurrence and hospitalization outcomes were assessed
over a 15-month time period.
Results—As compared to 100% of the 304 trial participants, only 296/608 (49%) historical
controls received antibiotics within an average of 20 weeks after new onset Pa. Pa recurrence
occurred among 104/298 (35%) of the trial participants as compared to 295/549 (54%) of
historical controls (19% difference, 95% CI: 12%, 26%, p<0.001). No significant differences in
the incidence of hospitalization were observed between cohorts.
Conclusions—Protocol-based antimicrobial therapy for newly acquired Pa resulted in a lower
rate of Pa recurrence but comparable hospitalization rates as compared to a historical control
cohort less aggressively treated with antibiotics for new onset Pa.
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Introduction
The clinical impact of chronic infection with Pseudomonas aeruginosa (Pa) on morbidity
and mortality is well established among individuals with cystic fibrosis (CF)(1, 2). Treatment
with anti-pseudomonal antibiotics to delay or prevent chronic Pa infection is critical during
the early infection period because of a limited “window of opportunity” during which Pa
infection is characterized by non-mucoid phenotype, antibiotic sensitivity, and low
density(3-9). Over the last decade, many studies have demonstrated the microbiologic
efficacy of initial Pa eradication regimens (10-15), and the standard of care has thus
transitioned to treating Pa positive cultures independent of concurrent symptoms (16-18).
Treggiari et. al.(19) reported that among 146 pediatric CF clinical centers in the United States
in 2003, 93% of children who received anti-pseudomonal treatment at first Pa infection
were asymptomatic at the time of presentation. Only two placebo-controlled studies have
been performed to assess the impact of initial eradication therapy on microbiologic
outcomes(11, 12, 14), but both were limited to small sample sizes and did not evaluate impact
of this therapy on clinical outcomes.
The Early Pseudomonas Infection Control (EPIC) randomized trial was designed to
rigorously evaluate the impact of four different early anti-pseudomonal treatment regimens
on long term clinical and microbiologic efficacy outcomes in a large cohort of CF children
less than 13 years of age with recent isolation of Pa from respiratory cultures (19, 20). Over
an 18-month period, the trial compared the effects of cycled antibiotic therapy administered
in quarterly cycles regardless of results of quarterly respiratory cultures or symptoms with
culture-based therapy administered only when Pa was isolated from quarterly cultures. All
participants received an initial antibiotic course at study entry consisting of 28 to 56 days of
tobramycin inhalation solution (TIS) with or without oral ciprofloxacin to promote initial Pa
eradication. The trial revealed no differences between treatment regimens with respect to
key microbiologic and clinical outcomes including Pa recurrence, pulmonary exacerbations,
Mayer-Hamblett et al. Page 2






















and hospitalizations (21). The overall low rate of Pa recurrence (35%) and hospitalization
(26%) observed in the 18-month trial contributed to the subsequent recommendation of use
of initial therapy with TIS at the time of new onset Pa followed by close microbiologic
surveillance(22). However, due to the lack of a placebo-control in the trial, negative cultures
following the initial cycle could have reflected spontaneous clearance rather than efficacy of
the targeted therapeutic approach(22). As antimicrobial treatment based on culture positivity
alone to eradicate newly isolated Pa became standard of care in the U.S. in the early 2000s,
a control group receiving placebo and only symptom-based anti-pseudomonal antibiotic
therapy was not considered ethical at the time of trial initiation in 2004(20). It thus remains
unclear whether microbiologic and clinical outcomes observed in the clinical trial, including
relatively low Pa recurrence and hospitalization rates, were different than those that would
have been observed with treatment of Pa driven more heavily by the presence of respiratory
symptoms than on culture positivity alone.
The objectives of the present study were to compare key outcomes between children
enrolled in the EPIC trial who were treated with a standardized Pa eradication protocol and
historical controls observed prior to the widespread adoption of an anti-pseudomonal
eradication regimen and from an era in which treatment of Pa was driven primarily by the
presence of respiratory symptoms(14). In the absence of the ability to compare to placebo,
the availability of historical controls provides a unique opportunity to evaluate the
effectiveness of standardized eradication therapies as has been done in a prior study of
inhaled colistin(23). Our primary hypothesis was that both the frequency of Pa recurrence,
defined as the first positive culture after an initial therapy period, and occurrence of
hospitalizations would be significantly reduced in the clinical trial cohort who received a
standardized, protocol based therapy with TIS as compared to the historic controls.
Materials and Methods
Cohort Selection
The trial cohort was comprised of 304 eligible and randomized participants in the EPIC
clinical trial as previously described(20) (ClinicalTrials.gov number NCT00097773).
Eligibility criteria from the clinical trial were used as the primary selection criteria for the
historical control cohort (E-Table 1, Online Supplement).
The historical control cohort was obtained from the Epidemiologic Study of Cystic
Fibrosis(24) (ESCF), a prospective encounter-based observational study initiated in 1994 and
designed to characterize the natural history and medication usage of over 30,000 participants
with CF, providing the most comprehensive historical data for comparison with the EPIC
trial cohort. Controls who met the eligibility criteria outlined in E-Table 1 during the years
1995 to 1998 were selected in order to reflect treatment practices before the widespread
commercial availability of TIS(25). To achieve a larger sample size and increase precision, a
2:1 matching strategy based on age and gender was used to identify 608 controls to compare
with the 304 clinical trial participants.
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This study was approved by the Institutional Review Board (IRB) at Seattle Children's
Hospital, Seattle, Washington. Written informed consent was obtained from participants or
their guardians as required by the IRBs at the participating institutions.
Study Design
Based on the date of the new Pa culture which defined eligibility into each of the cohorts (E-
Table 1), two distinct data collection periods were defined: the initial therapy period and the
follow-up period (Figure 1). The initial therapy period enabled characterization of the early
treatment response to antimicrobial therapy directed against new onset Pa. For EPIC clinical
trial participants, the initial therapy period was defined as the time between new onset Pa
and up to 10 weeks following the baseline visit in the clinical trial. The clinical trial allowed
up to a 6-month window between the new onset Pa culture that defined eligibility and the
baseline visit, during which time participants could receive one course of anti-pseudomonal
antibiotics. After randomization and during the first quarter of the trial, all participants were
given 1-2 courses of anti-pseudomonal antibiotics to promote initial Pa eradication,
irrespective of treatment group assignment(20). For the ESCF controls, the length of the
initial therapy period for each control was determined based on that of their matched clinical
trial participant starting from the time of new onset Pa. The follow up period for each
clinical trial participant was defined as the time between the end of the initial therapy period
(approximately 10 weeks into the clinical trial) and the day of their final study visit at
approximately 70 weeks post-randomization (Figure 1). The follow up times were derived
for each EPIC clinical trial participant and similarly used to derive matched follow up
periods for their ESCF historical controls.
Study Endpoints
The primary endpoint for comparison between cohorts was the proportion with recurrent Pa,
defined as at least one positive respiratory culture for Pa during the follow up period, and
the secondary endpoint was the proportion of participants hospitalized for any reason during
the follow up period.
Statistical Methods and Precision
Demographic and baseline clinical characteristics of the cohorts were summarized
descriptively in conjunction with the frequency of anti-pseudomonal antibiotic usage. The
proportions of participants with Pa recurrence and with hospitalization were summarized for
each cohort with corresponding 95% confidence intervals derived using the Newcombe-
Wilson method(26), and p-values for differences between cohorts were obtained using a two-
sided 0.05 level of significance Fisher exact test. Due to the exploratory nature of this study,
no formal hypothesis testing was performed and an a priori precision estimate utilizing a
confidence interval approach was derived for the primary comparison of interest. A total of
104/298 (35%) of participants in the clinical trial experienced Pa recurrence after the initial
therapy period. Assuming this proportion is 10% higher among the 608 ESCF historical
controls, the 95% confidence intervals corresponding to the 10% difference would be (3%,
17%). Analyses were performed using the statistical software SAS, version 9.1.3 (SAS
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Institute Inc., Cary, NC), R statistical package version 2.9.1 (R Foundation for Statistical
Computing, Vienna, Austria), and Stata version 10.1 (StataCorp LP, College Station, TX).
Sensitivity Analysis
Under the hypothesis that the clinical trial cohort would have better outcomes than the
historical controls, a sensitivity analysis was performed to assess whether a result of better
outcomes among clinical trial participants could be explained merely by clinical trial
participation bias. To evaluate this potential bias, the outcomes of Pa recurrence and
hospitalization were also assessed among a concurrent observational control cohort not
enrolled in a clinical trial and obtained from the EPIC observational study, an ancillary study
to the Cystic Fibrosis Foundation National Patient Registry(20). This longitudinal
observational study was conducted in parallel with the EPIC clinical trial at the same sites
and enrolled 1787 children with CF <13 years of age never colonized with Pa or negative
for Pa for at least 2 years prior to enrollment. Participants who turned Pa positive were
offered enrollment in the EPIC clinical trial. All children (n=231) who were eligible for the
clinical trial based on eligibility criteria for new onset Pa as defined for the clinical trial (E-
Table 1), but did not enroll, comprised the concurrent control cohort with which sensitivity
analyses were performed.
Results
Baseline Characteristics and Follow-Up Time
The EPIC clinical trial cohort was comprised of 304 participants with demographic and
baseline clinical characteristics summarized in Table 1. Notably, FEV1 % predicted in the
historical controls was significantly lower than the trial participants (p=0.004). The number
of visits recorded during the initial therapy and follow-up periods were well balanced
between the cohorts with an average of 3 visits during the 4.6 month initial therapy period in
the clinical trial cohort as compared to 2.4 visits in the historical controls. During the follow-
up period, an average of 5.6 visits were available from the clinical trial cohort over an
average 13 months as compared to 4.9 visits from the historical controls over the
comparable time period.
Antibiotic Use in the Initial Therapy Period
There were significant differences in antibiotic usage between the cohorts during the initial
therapy period (Table 2). By design, all 304 (100%) of the clinical trial participants received
inhaled antibiotics, specifically TIS. In contrast, only 184/608 (30%) of the historical
controls had documented use of inhaled antibiotics, of whom 129/184 (70%) used TIS. Of
the 227 (75%) EPIC trial participants who received oral antibiotics, 152/227 (67%) received
oral ciprofloxacin as a protocol-based therapy in combination with TIS. In contrast, 114/608
(19%) of historical controls received oral antibiotics, with the majority receiving oral
quinolones (69/114 [61%]). Use of IV antibiotics during the initial therapy period among the
historical controls was slightly higher than that among the EPIC trial participants with
108/608 (18%) historical controls having documented use as compared to 31/304 (10%)
EPIC trial participants.
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Antibiotic Use in the Follow-Up Period
Similar trends in antibiotic use were observed throughout the follow up period among the
clinical trial participants, with 289/304 (95%) using inhaled, oral, or IV antibiotics (Table 2).
Significant differences in antibiotic use remained between the EPIC trial participants and the
ESCF historical controls, with 37% fewer (95% CI: -41%, -32%) historical controls, or 58%
overall, using antibiotics during the follow up period.
Pa Recurrence
While the majority of clinical trial participants had 4 or more cultures available during the
follow up period, this was not the case for the historical controls and thus Pa recurrence
rates are reported both overall and stratified by culture frequency (Table 3). Overall,
104/298 (35%) of trial participants experienced Pa recurrence during the clinical trial. In
contrast, 295/549 (54%) of historical controls had Pa recurrence (19% difference, 95% CI:
12%, 26%, p<0.001). Importantly, the differences in Pa recurrence rates were consistent
across the differing culture frequencies (Table 3). Pa recurrence rates did not significantly
differ between historical controls who received antibiotics in the initial therapy period and
those who did not (135/269 [50%] vs. 160/280 [57%] respectively, 7% difference, p=0.11).
There was also a striking difference between EPIC trial participants and historical controls
in terms of the proportion who developed persistent Pa infection, defined as at least two
positive cultures during the follow-up period, with 49/292 (17%) of EPIC trial participants
developing persistent Pa infection as compared to 129/396 (33%) of historical controls
(16% difference, 95% CI 9%, 22%, p<0.001).
Hospitalizations
Despite significant differences between EPIC trial participants and historical controls in
early antibiotic use at new onset Pa, no significant difference in subsequent all cause
hospitalization was observed. A total of 79/304 (26%) of EPIC trial participants were
hospitalized during the follow up compared to 124/608 (20%) of the historical controls
(difference 6%, 95% CI: 0%,12%, p=0.06). Hospitalization rates were slightly higher
however among historical controls who received antibiotics during the initial therapy period
with 72/296 (24%) hospitalized as compared to 52/312 (17%) historical controls who did not
receive antibiotics during the initial therapy period (7%, difference, 95% CI 1%,14%,
p=0.02).
Sensitivity Analyses
There were 231 children from participating sites of the clinical trial who were enrolled in the
concurrent EPIC observational study, experienced new onset Pa during the trial enrollment
period, and who did not enroll in the clinical trial. The mean age of the cohort was 6.2 years
(SD=3.4). The primary reason for non-enrollment into the trial was the family declining to
participate (105/231, 46%) with an additional 29/231 (13%) not approached for enrollment
into the trial and the remainder providing unknown reasons for non-enrollment. A total of
152/231 (66%) received antibiotic therapy within the first few months following new onset
Pa. Comparable to the trial participants, nearly all received at least one course of antibiotics
over the follow up period (n=194/231, 84%). Pa recurrence and hospitalization outcomes
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were comparable between the trial participants and non-participants with 79/229 (34%, 95%
CI: 28%, 40%) of non-trial participants with culture results available experiencing Pa
recurrence and 49/231 (21%, 95% CI: 16%, 27%) hospitalized during the follow up period
following new onset Pa. These rates were not significantly different between those receiving
antibiotics during the initial therapy period and those not receiving antibiotics during the
initial therapy period. Unlike the trial participants for whom the majority (91%) had 4 or
more cultures during the follow-up period, only 119/231 (75%) had 4 or more cultures
among the non-trial participants.
Discussion
This study provides a unique opportunity to evaluate the results from a randomized clinical
trial studying the effectiveness of protocol-based anti-pseudomonal treatment regimens for
new onset Pa among children with CF versus historic, less standardized treatment
approaches. We hypothesized that trial participants who received anti-pseudomonal therapy
in response to new onset Pa according to a study protocol would have improved outcomes in
comparison to a standard of care used before the aggressive use of an initial eradication
therapy. We documented that the approach to treatment of early Pa infection has changed
over the past 15 years in the U.S with significantly higher use of both inhaled and oral
antibiotics. This change towards earlier and more frequent antibiotic use was associated with
significantly lower Pa recurrence rates in the clinical trial participants as compared to the
historical controls. This result is consistent with those from other studies regarding the
efficacy of inhaled antibiotics in initial eradication therapy among young children with
CF(10-15, 23). Failure to initially eradicate Pa and frequent Pa recurrence has also been
associated with higher risk of developing an acute pulmonary exacerbation, and thus the
recurrence of Pa is an important outcome indicative of the transition to chronic Pa infection
and its associated morbidity (27).
Despite significant differences in the use of antibiotics for new onset Pa between clinical
trial participants and historical control cohorts, no significant differences in hospitalization
rates were observed. Another clinically relevant endpoint would have been pulmonary
exacerbations, as this endpoint is more specific to respiratory infections and can capture less
severe events than those requiring hospitalization; however, inconsistency in the definition
of exacerbation across the cohorts did not allow the use of this endpoint in this study(28). IV
antibiotic treatment is often a surrogate for more severe pulmonary exacerbations. However,
as with the hospitalization endpoint, it was not significantly different between the cohorts
following initial treatment for new onset Pa. These results suggest that differences in Pa
culture positivity between the cohorts did not translate into differences in clinical outcome
as captured by hospitalizations over the course of the study follow-up.
Our sensitivity analysis utilizing concurrent controls from the EPIC observational study
suggests that the protocol based therapy given during the clinical trial for Pa eradication
resulted in similar clinical and microbiologic outcomes as compared to the control cohort
not participating in the trial and receiving contemporary standard of care treatment. We
documented that contemporary treatment with increased use of early anti-pseudomonal
antibiotics was associated with a reduction in the frequency of Pa recurrence as compared
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with the historical controls. This is a key result needed to benchmark the outcomes observed
in the clinical trial, and confirm that trial results were not due to trial participation bias.
There are several limitations to our study, in particular that differences between the trial
cohort and historical controls may be attributable to other differences in care between the
cohorts that have been introduced over the years including changes in infection control
practices, changes in use of chronic therapy, and improvements in nutritional care. Further,
antibiotic use and isolation of Pa from respiratory cultures may have been underestimated in
the historical controls. Specifically, there were differences in culture frequency between the
cohorts that could have resulted in under-detection of Pa among the historical controls, and
thus our estimate of the difference between the cohorts in Pa recurrence rates may be an
underestimate of the true difference in rates. In addition, although the historic controls were
chosen based on eligibility criteria similar to those utilized in the clinical trial for the
definition of new onset Pa, there were some secondary inclusion and exclusion criteria that
were not available. Lack of availability of lifetime history of Pa positivity prior to the
initiation of ESCF for the historical controls, and lung function for younger children,
precluded us from being able to match on these potentially important factors. Thus, the
historical control cohort may be different than the trial participants in terms of other
unmeasurable characteristics. It is uncertain however whether any selection bias in the
historic control cohort would induce better or poorer outcomes.
This study evaluates the results of a non-placebo controlled clinical trial compared to
historical standard of care, and demonstrates the shift in approach to treatment of early Pa
infection in the U.S. in the past 15 years and the impact of these changes on microbiologic
and clinical outcomes. The use of observational registries for studies such as this is critical
in the orphan disease setting and enables evaluation of the generalizability of the results of a
clinical trial. The ability of this study to benchmark the EPIC clinical trial results ultimately
demonstrates that the protocol based therapy received during the trial is effective in
preventing Pa recurrence when compared with less aggressive antibiotic therapy following
acquisition of Pa.
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Figure 1. Schematic of Data Collection and Timing
The initial therapy period for the EPIC clinical trial participants was defined as the time
between the Pa qualifying culture and 10 weeks post their baseline visit in the clinical trial.
The clinical trial allowed up to a 6-month window between the new onset Pa that defined
eligibility and the baseline randomization visit and during this time, participants were
allowed limited anti-pseudomonal antibiotics.(20) For the historical controls, the length of
the initial therapy period for each control was determined based on that of their matched
clinical trial participant. The follow up period for each clinical trial participant was defined
as the time between the end of the initial therapy period (approximately 10 weeks into the
Mayer-Hamblett et al. Page 15






















clinical trial) and the day of their final study visit at approximately 70 weeks post-
randomization. The follow up times were derived for each clinical trial participant and
similarly used to derive matched follow up periods for the controls.
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Table 1
Demographic and Baseline Clinical Characteristics
EPIC Clinical Trial (N=304) ESCF Historical Controls (N=608)
Gender, n (%)




White (non-Hispanic) 285 (93.8) 544 (89.5)
Black (non-Hispanic) 7 (2.3) 19 (3.1)
Hispanic 4 (1.3) 32 (5.3)
Other/Mixed/Unknown 8 (2.6) 13 (2.1)
Genotype, n (%)
Delta F508 Homozygous 149 (49.0) 266 (43.8)
Delta F508 Heterozygous 116 (38.2) 165 (27.1)
Other 24 (7.9) 30 (4.9)
Unknown 15 (4.9) 147 (24.2)
Age at New Onset Pa, yrs
Mean (SD) 5.5 (3.5) 5.5 (3.5)
Min, Max 0.1, 13.0 0.50, 12.96
Age Group, years, n (%)
1-3 93 (30.6) 189 (31.1)
>3-6 91 (29.9) 174 (28.6)




Mean (SD) 96.2 (16.7) 90.9 (18.3)




Spirometry measures are only available for those old enough to perform the procedure and corresponded to the closest visit on or after new onset
Pa.
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Table 2
Summary of antibiotic therapy received during the initial therapy and follow-up periods after new onset Pa.




No. (%) Participants 304 (100%) 184 (30.3%)
Oral Antibiotics
No. (%) Participants 227 (74.7%) 114 (18.8%)
IV Antibiotics
No. (%) Participants 31 (10.2%) 108 (17.8%)
Any Antibiotic
No. (%) Participants 304 (100%) 296 (48.7%)
95% CI (98.8%, 100%) (44.7%,52.7%)
Diff. as Compared to Trial
Participants - −51.3%





No. (%) Participants 218 (71.7%) 241 (39.6%)
Oral Antibiotics
No. (%) Participants 276 (90.8%) 174 (28.6%)
IV Antibiotics
No. (%) Participants 62 (20.4%) 113 (18.6%)
Any Antibiotic
No. (%) Participants 289 (95.1%) 355 (58.4%)
95% CI (92.0%,97.0%) (54.4%,62.2%)
Diff. as Compared to Trial
Participants - −36.7%




The initial therapy period for the EPIC clinical trial participants was defined as the time between the Pa qualifying culture and 10 weeks post their
baseline visit in the clinical trial. For the ESCF controls, the length of the initial therapy period for each control was determined based on that of
their matched clinical trial participant.
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2
The follow up period for each clinical trial participant was defined as the time between the end of the initial therapy period (approximately 10
weeks into the clinical trial) and the day of their final study visit at approximately 70 weeks post-randomization. The follow up times were derived
for each clinical trial participant and similarly used to derive matched follow up periods for the controls.
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Table 3
Proportion of participants with recurrent Pa by the number of cultures obtained during the follow-up period.
EPIC Clinical Trial (N=304) ESCF Historical Controls (N=608)
No. (%) with Recurrent Pa
Among those w/1 culture 0/6 (0%) 69/153 (45.1%)
Among those w/2 cultures 1/5 (20.0%) 79/148 (53.4%)
Among those w/3 cultures 1/10 (10.0%) 47/83 (56.6%)
Among those w/4+ cultures 102/277 (36.8%) 100/165 (60.6%)
Overall 104/298 (34.9%) 295/549 (53.7%)
95% CI (29.7%,40.5%) (49.6%,57.9%)
Overall Diff. as Compared
to Trial Participants - 18.8%
95% CI - (11.9%,25.5%)
p<0.001
CI= Confidence Interval; Diff = Difference
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